Evidence map›Paper›PMID 26108661›Full record

ArticleAmerican journal of physiology. Cell physiology2015

Endothelial cell tumor growth is Ape/ref-1 dependent.

Ayan Biswas, Savita Khanna, Sashwati Roy, Xueliang Pan, Chandan K Sen, Gayle M Gordillo

Registry-linked trialOpen access · greenAbstract read
In one paragraph

Article in American journal of physiology. Cell physiology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04020419 (Natural Berry Extract Treatment of Hemangiomas), which is not on this map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04020419 early_phase1terminatednot on this mapstarted 2020, after this paper: background citation

Natural Berry Extract Treatment of Hemangiomas

TypeinterventionalSponsorGayle GordilloRan2020 to 2023Enrolled12ConditionsHemangiomaArmsPediaBerry
3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Ref-1/APE1 Inhibition with Novel Small Molecules Blocks Ocular Neovascularization.The Journal of pharmacology and experimental therapeutics · 2018
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Ayan BiswasDepartment of Plastic Surgery, The Ohio State University Wexner Medical Center, Columbus, Ohio; Davis Heart and Lung Research Institute, The Ohio State University Wexner Medical Center, Columbus, Ohio; and.
Savita KhannaDepartment of Surgery, The Ohio State University Wexner Medical Center, Columbus, Ohio; Davis Heart and Lung Research Institute, The Ohio State University Wexner Medical Center, Columbus, Ohio; and.
Sashwati RoyDepartment of Surgery, The Ohio State University Wexner Medical Center, Columbus, Ohio; Davis Heart and Lung Research Institute, The Ohio State University Wexner Medical Center, Columbus, Ohio; and.
Xueliang PanCenter for Biostatistics, The Ohio State University Wexner Medical Center, Columbus, Ohio.
Chandan K SenDepartment of Surgery, The Ohio State University Wexner Medical Center, Columbus, Ohio; Davis Heart and Lung Research Institute, The Ohio State University Wexner Medical Center, Columbus, Ohio; and.
Gayle M GordilloDepartment of Plastic Surgery, The Ohio State University Wexner Medical Center, Columbus, Ohio; Davis Heart and Lung Research Institute, The Ohio State University Wexner Medical Center, Columbus, Ohio; and gayle.gordillo@osumc.edu.
The Ohio State University Wexner Medical Center · US

Funding

Mechanisms Regulating Hemangioendothelioma: A Plastic Surgeon's ChallengeR01GM095657 · NIGMS · OHIO STATE UNIVERSITY · PI GORDILLO, GAYLE M · 2011 to 2020
$2.6M
Novel Regulators of Wound AngiogenesisR01GM108014 · NIGMS · OHIO STATE UNIVERSITY · PI SEN, CHANDAN K · 2015 to 2018
$1.2M
NIGMS NIH HHS R01 GM095657NIGMS NIH HHS R01-GM-095657NIGMS NIH HHS R01 GM108014
6 · The paper itself

Abstract

Tumor-forming endothelial cells have highly elevated levels of Nox-4 that release H2O2 into the nucleus, which is generally not compatible with cell survival. We sought to identify compensatory mechanisms that enable tumor-forming endothelial cells to survive and proliferate under these conditions. Ape-1/ref-1 (Apex-1) is a multifunctional protein that promotes DNA binding of redox-sensitive transcription factors, such as AP-1, and repairs oxidative DNA damage. A validated mouse endothelial cell (EOMA) tumor model was used to demonstrate that Nox-4-derived H2O2 causes DNA oxidation that induces Apex-1 expression. Apex-1 functions as a chaperone to keep transcription factors in a reduced state. In EOMA cells Apex-1 enables AP-1 binding to the monocyte chemoattractant protein-1 (mcp-1) promoter and expression of that protein is required for endothelial cell tumor formation. Intraperitoneal injection of the small molecule inhibitor E3330, which specifically targets Apex-1 redox-sensitive functions, resulted in a 50% decrease in tumor volume compared with mice injected with vehicle control (n = 6 per group), indicating that endothelial cell tumor proliferation is dependent on Apex-1 expression. These are the first reported results to establish Nox-4 induction of Apex-1 as a mechanism promoting endothelial cell tumor formation.

Indexed as

Cell ProliferationAnimalsBenzoquinonesCell SurvivalDNA-(Apurinic or Apyrimidinic Site) LyaseEndothelial CellsFemaleMiceMice, 129 StrainNeoplasmsPropionatesApex1 protein, mouseBenzoquinonesDNA-(Apurinic or Apyrimidinic Site) LyaseE 3330PropionatesAP-1 transcription factorc-Jun transcription factorDNA damage responseendothelial cellhemangioendotheliomahemangiomamonocyte chemoattractant protein-1, Ape-1/ref-1Nox-4tumor cell biology

Identifiers

PMID26108661
PMCPMC4556895
OpenAlexW2269890855

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.